However, over the past 20 years, most patients with HER2+ breast cancer have received adjuvant or neoadjuvant trastuzumab (47, 118, 119), so it is reasonable to assume that the great majority of relapsed patients had been treated with trastuzumab, as either combination or monotherapies. The gene discussed is ERBB2; the disease is breast carcinoma.